Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 10/20 | 0.52 |
| ▸ | LDHB | P07195 | 8/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6604456 | 0.74 | LDHA (0.48) | LDHALDHBALDH1A1EGFRKDM4E | |
| SCHEMBL6603168 | 0.74 | LDHA (0.69) | LDHALDHBALDH1A1 | |
| SCHEMBL6602959 | 0.73 | LDHA (0.41) | LDHAOPRM1OPRD1EGFR | |
| SCHEMBL6605191 | 0.73 | LDHA (0.47) | LDHALDHBALDH1A1 | |
| SCHEMBL6603207 | 0.73 | LDHA (0.47) | LDHALDHB | |
| SCHEMBL4258794 | 0.73 | CFTR (0.45) | LDHALDHBCFTRGOPCALDH1A1 | |
| SCHEMBL6604202 | 0.72 | LDHA (0.59) | LDHALDHB | |
| SCHEMBL6605035 | 0.71 | LDHA (0.42) | LDHALDHBEGFR | |
| SCHEMBL6606184 | 0.71 | LDHA (0.45) | LDHALDHB | |
| SCHEMBL6603498 | 0.71 | LDHA (0.57) | LDHALDHB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0729463-B1 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE DAVIS & CO (US) | 2002-05-22 | — | — | EP | claimed |
| EP-0729463-A1 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE DAVIS & COMPANY (US) | 1996-09-04 | — | — | EP | claimed |
| WO-1995014011-A2 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | claimed |
| EP-1142887-B1 | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents | PARKE DAVIS & CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-0729463-B1 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE DAVIS & CO (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1142887-A1 | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents | PARKE, DAVIS & COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| US-5936128-A | BENZENETHIOL COMPOUNDS AS INTERMEDIATES; BACTERICIDES, VIRICIDES; HIV | WARNER-LAMBERT COMPANY (US) | 1999-08-10 | — | — | US | disclosed |
| US-5840751-A | ADMINISTERING IN THE TREATMENT OF INFECTION OR DISEASE CAUSED BY A RETROVIRUS | WARNER-LAMBERT COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| US-5789440-A | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents | WARNER-LAMBERT COMPANY (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0729463-A1 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE DAVIS & COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0729464-A1 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995014012-A1 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995014011-A2 | 5,6-DIHYDROPYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |